Drug profile

The FDA adverse-event record for Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment

Name: Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

49 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment. Species, reactions, and outcomes follow.

#1137 of 2,679
by report volume (all drugs): 49
adverse-event reports: 12.2%
death-coded share: Dog
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment ranks #1131 of 2679 by total reports (49). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #1131
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment has 49 reports now versus 46 in that prior snapshot: 3 more (6.5%).

Report change: +3
Death-coded reports: +0
Death-coded share: −0.8 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment changes

Signature read: death-coded report count at 6 is the most distinctive stamp on Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

12.2%

Death-coded share of reports

Active Ingredients

Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Dog 39

Cat 10

Most Affected Breeds

Domestic Shorthair 8

Retriever - Labrador 6

Shiba Inu 4

Spaniel - Cocker American 2

Bulldog - French 2

Dog (other) 2

Dog (unknown) 2

Chihuahua 2

Terrier - Irish Soft-coated Wheaten 1

Retriever - Golden 1

Most Reported Reactions

Vomiting 12

Lethargy (see also Central nervous system depression in 'Neurological') 10

Other abnormal test result NOS 5

Seizure NOS 5

Decreased appetite 5

Lack of efficacy - NOS 4

Ear discharge 4

Behavioural disorder NOS 4

Dehydration 3

Hyperglycaemia 3

Death by euthanasia 3

Other ear disorder NOS 3

Outcome Breakdown

Ongoing

22 (44.9%)

Outcome Unknown

13 (26.5%)

Recovered/Normal

8 (16.3%)

Died

3 (6.1%)

Euthanized

3 (6.1%)

Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Nystatin-Neomycin Sulfate-Thiostrepton-Triamcinolone Acetonide Ointment (#1137 of 2,679 by report volume); death-coded 12.2%. PlainBreed drug row · death-coded report count stamp 6 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →